Background {#Sec1}
==========

Esophageal cancer (EC) is one of the most malignant tumors worldwide, ranking seventh in cancer incidence and sixth in cancer mortality in 2018 \[[@CR1]\]. Esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) are two main histological types. EAC is the main histological type in developed countries whereas ESCC predominates in eastern Asia and Africa \[[@CR2]\]. The prognosis of esophageal cancer is poor; the 5-year survival rate of EC in the United States is 19%, in Europe 12.4%, and in China 20.9% \[[@CR3]--[@CR5]\].

The prognosis of esophageal cancer is influenced by many different factors \[[@CR6]\]. Noteworthy, increasing evidence is highlighting the pivotal effects of nutritional factors on cancer prognosis and survival: natural ingredients such as lycopene and beta-carotene in the plant food could inhibit EC109 cell viability \[[@CR7]\], dietary interventions could improve diet quality in cancer survivors \[[@CR8]\], and nutritional support could improve esophageal cancer prognosis by improving treatment compliance, reducing toxicity and enhancing the immune response \[[@CR9]\]. However, most studies focused on the roles of perioperative nutrition support in postoperative complications \[[@CR10], [@CR11]\], and the results from epidemiological studies on the associations between dietary factors and EC prognosis are inconclusive \[[@CR12]--[@CR15]\]. A meta-analysis showed that pre-diagnosis alcohol drinking increased risk of death in ESCC rather than in EAC \[[@CR16]\], however, some new evidence has emerged after this study published and the pooled results are needed to be updated.

Therefore, by summarizing the results of observational studies, this systematic review and meta-analysis was conducted to evaluate the association between food and its components intake and risk of mortality among patients with esophageal cancer, with addressing the difference in histology and the difference between all-cause mortality and cancer-specific mortality.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

Literatures published up to October. 2019 were systematically searched through four English databases (PubMed, Web of Science, OVID, ProQuest) and two Chinese databases (CNKI and Wanfang). PRISMA statement for conducting and reporting meta-analysis of observational studies was followed \[[@CR17]\]. The search strategy was as follows: \[(vegetables OR fruits OR meat OR poultry OR drinking OR alcohol OR beer OR liquor OR beverage OR nuts OR soy OR cereal OR bean OR nutrients OR micronutrients OR macronutrients OR dietary fiber OR vitamin OR phytochemicals OR lignan OR phytoestrogen OR dietary OR diet OR food OR dietary pattern OR dietary supplements)\] AND \[(esophageal cancer OR esophageal adenocarcinoma OR esophageal squamous cell carcinoma OR esophageal neoplasm OR esophageal tumor OR cancer of esophagus OR esophageal neoplasms)\] AND \[(Survival OR prognosis OR mortality OR recurrence OR replase OR progression OR medical futility OR treatment outcome OR treatment failure OR cause of death OR fatal outcome)\]. Language and countries were not restricted during the whole searching process.

Two researchers (LP Sun & LB Yan) independently conducted the literature retrieval, identified potential studies, extracted information from the included papers, and assessed the quality of included studies. Discrepancies were settled down by group discussion with other two professionals (X LIU & CX Zhang). The titles and abstracts of initially identified papers were firstly reviewed, and then the full texts of the selected papers were reviewed to determine eligibility. To avoid omission of literatures, backward and forward citation tracking in both Web of Science and Scopus were also used to identify articles.

Study selection criteria {#Sec4}
------------------------

Studies meeting the following conditions would be included: (i) study design was cohort study with esophageal cancer patients; (ii) the consumption of food and/or its components but not supplementations was accessible; (iii) prognostic outcomes included all-cause mortality, esophageal cancer-specific mortality or esophageal cancer recurrence; (iv) the hazard ratio (HR) or relative risk with 95% confidence interval (95% CI) were reported or could be calculated. When there were papers from the same study or covering the same population, only the most comprehensive or latest data was selected. Case reports, cross-sectional studies, editorials, abstracts, reviews, articles without full text, duplicated studies, animal studies and vitro studies were excluded.

Data extraction {#Sec5}
---------------

Data and information were extracted from the included studies, including name of the first author, publication year, country, sources of patients, sample size, histological type, follow-up duration, stage/grade grouping, dietary exposure, dietary assessments, outcomes, comparison method, effect size, confounders and covariates.

Quality assessment {#Sec6}
------------------

Quality of the included papers was evaluated according to the Newcastle-Ottawa Scale (NOS) Criteria for non-randomized studies \[[@CR18]\]. A maximum total 9 points were assigned to each study, with a maximum of 4 for selection, 2 for comparability and 3 for outcome. Studies were considered to be of high quality (\> 6), median quality (4\~6) or low quality (≤3, \[[@CR19]\]).

Statistical analyses {#Sec7}
--------------------

Meta-analysis was conducted to estimate the pooled HR with 95% CI by comparing the highest with the lowest categories of dietary intake in each selected item. A random effect model was selected in the meta-analysis \[[@CR20]\]. Heterogeneity between studies was measured using *Q* and *I*^2^ statistics. Sensitivity analysis was conducted by excluding the study one by one from the pooled results, by excluding the studies not reporting adjusted effects, and by excluding the studies not collecting information of stage and severity of esophageal cancer. The meta-analysis with crude HRs obtained from univariate analysis was also conducted. Publication bias was tested by funnel plot with Begg's tests \[[@CR21]\]. A power calculator used to estimate statistical power of meta-analyses \[[@CR22]\]. Statistical analysis was completed in Stata 15.1 (Stata Corporation, College Station, TX) and R software (version 3.5.3).

Results {#Sec8}
=======

Literature retrieval {#Sec9}
--------------------

Figure [1](#Fig1){ref-type="fig"} shows the flowchart of literature selection. After removal of 4215 duplicates, 3795 potentially eligible records were left, of which 3677 were excluded after reviewing the titles and abstracts. Finally, 15 eligible cohort studies \[[@CR12]--[@CR15], [@CR23]--[@CR33]\] containing 6826 esophageal cancer patients were identified through full text review of 118 studies. The most common reasons for exclusion were study designs, lack of data on dietary exposure and no outcomes of interest. Fig. 1Flowchart of the literature selection. Abbreviation: WOS, Web of Science; HR, hazard ratio; RR, relative risk; OR, odd ratio; EC, esophageal cancer; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma. CNKI and Wanfang are Chinese database, CNKI: <http://new.oversea.cnki.net/index/>; Wanfang: <http://www.wanfangdata.com.cn/resource_nav/index.do>

Characteristics of included studies {#Sec10}
-----------------------------------

Characteristics and study quality of the included studies are shown in Table [1](#Tab1){ref-type="table"}. Briefly, 7 cohort studies recruited patients from completed case-control studies \[[@CR12]--[@CR14], [@CR23], [@CR29], [@CR31], [@CR32]\] and the other eight were new established cohorts \[[@CR15], [@CR24]--[@CR28], [@CR30], [@CR33]\]; three studies were conducted in USA \[[@CR12], [@CR13], [@CR23]\], six in China \[[@CR15], [@CR24], [@CR25], [@CR27], [@CR30], [@CR32]\], two in Australia \[[@CR29], [@CR31]\], one in South Korea \[[@CR28]\], one in Sweden \[[@CR14]\], one in Japan \[[@CR26]\] and one in Iran \[[@CR33]\]; one study only recruited male patients \[[@CR28]\] and the others included both genders. The median follow-up duration ranged from 0.8 to 12.1 years. Only three studies reported the risk estimates without any adjustments \[[@CR23]--[@CR25]\], other 12 studies reported adjusted risk estimates. The most common adjusted confounders included age, gender, tumor stage, complications and treatments. With the exception of five studies \[[@CR23]--[@CR25], [@CR28], [@CR30]\], other ten studies collected information of stage and severity of esophageal cancer and adjusted for them when estimating the effect size. Eleven studies focused on ESCC \[[@CR13]--[@CR15], [@CR23]--[@CR27], [@CR29], [@CR30], [@CR32]\], 5 on EAC \[[@CR12]--[@CR14], [@CR23], [@CR31]\], and 3 on EC \[[@CR12], [@CR28], [@CR33]\]. Table 1Characteristics of included studies and quality scoreAuthor, reference, year,\
countrySources of cohort patientsFollow-up duration (years)Number and type of patientsStage/grade groupingExposureDietary assessmentsComparison categoriesAdjusted HR (95% CI)\
(highest vs. lowest) for mortalityAdjustmentsNOS starsPetrick et al. \[[@CR13]\], 2015, USAPopulation-based case--control studyMax: 7.5Median^a^:0.8 for EAC,0.9 for ESCC274 EAC191 ESCCPrimary invasive cases:localized, regional, distant, unknownTotal flavonoids, six classes of flavonoids (anthocyanidins, flavan-3-ols, flavanones, flavones, flavanols, and isoflavones), lignansA 104-item modified FFQEach were divided into 4 categories (mg/day):Total flavonoids:0--62.35,62.36--103.39,103.40--253.24, ≥253.25;Anthocyanidins:0--6.23,6.24--10.11,10.12--16.23,≥16.24;Flavan-3-ols:0--10.90,10.91--26.67,26.68--210.51, ≥210.52;Flavanones:0--8.63,8.64--32.94,34.95--49.00,≥49.01;Flavones:0--1.20,1.21--1.81,1.82--2.64,≥2.65;Flavonols:0--8.16,8.17--12.30,12.31--19.34,≥19.35;Isoflavones:0--0.31,0.32--0.46,0.47--0.62,≥0.63;Lignans:0--0.044,0.045--0.060,0.061--0.079,≥0.080All-cause mortalityFor EAC:Total flavonoids:0.98 (0.68, 1.41);Anthocyanidins:0.87 (0.60, 1.26);Flavan-3-ols:0.93 (0.65, 1.33);Flavanones:1.15 (0.79, 1.68);Flavones:0.83 (0.58, 1.19);Flavonols:0.94 (0.65, 1.37);Isoflavones:0.75 (0.49, 1.13);Lignans:0.78 (0.54, 1.14)For ESCC:Total flavonoids:0.91 (0.58, 1.44);Anthocyanidins:2.272 (0.66, 1.56);Flavan-3-ols:1.09 (0.69, 1.74);Flavanones:1.24 (0.76, 2.03);Flavones:2.272 (0.64, 1.54);Flavonols:0.93 (0.61, 1.40);Isoflavones:0.97 (0.60, 1.58);Lignans:0.61 (0.39, 0.96)Cancer stage and dietary energy intake7Miles et al. \[[@CR12]\], 2016, USAPopulation-based case--control studyMedian: 12.1108 EC74 EACWell differentiated, Poorly differentiated, UndeterminedSugary beverages including soft drinks and fruit juices (classified into SB1 and SB2^b^)NCI-block FFQMedian for soft drinks and fruit juices(g/day):soft drinks:4.0;fruit juices:0.71SB1 intake quartile point(g/day):(Q1)0.71,(Q2)11.81,(Q3) 40.00;SB2 intake quartile points(g/day)(Q1)3.04,(Q2)20.76,(Q3)45.29All-cause mortalityFor EC:soft drinks:2.29 (1.32,3.93);fruit juices:2.39 (1.34,4.30);SB1:2.58 (1.45,4.60);SB2:1.94 (1.06,3.53)For EAC:soft drinks:1.84 (0.92,3.68);fruit juices:1.60 (0.79,3.25);SB1:1.51 (0.72,3.16);SB2:1.44 (0.57,3.62)Age, sex, ethnicity, education, smoking, alcohol drinking, caloric intake, pathology type, and tumor differentiation grade8Shi et al. \[[@CR30]\], 2018, ChinaA new established patient cohortMedian: 4.08185 ESCCAJCC stage: Only included I and II stagePreserved vegetablesA modified FFQ2 categories (time/week):\< 1 and ≥ 1All-cause mortality1.58 (1.01,2.47)Age and sex7Lu et al. \[[@CR24]\], 2011, ChinaA new established patient cohortMedian: 3.5, (Min-Max: 0.03--4.66)120 ESCC patients underwent esophagectomyT stage: T1\~T4N stage: N0, N1M stage: M0, M1clinical stage: 1/2, 3/4FolateNIH-modified FFQ3 categories(ug/day):\< 30.0,30.0--95.4,≥95.5Cancer-specific mortality0.39 (0.20,0.78)Age, sex, TNM stage7Jing et al. \[[@CR25]\], 2012, ChinaA new established patient cohortMedian: 3.25,(Min-Max: 0.25--5)167 ESCCT stage: T1\~T4N stage: N0, N1M stage: M0, M1FolateA 65-item self-administered structured questionnaire3 categories(ug/day):\< 230,230--300,\> 300Cancer-specific mortality:0.45 (0.18,0.87)Age, sex, smoking, drinking, tumor sites, TNM stage, chemo-therapy and radio-therapy6Trivers et al. \[[@CR23]\], 2005, USApopulation- based, case-control studyMax: 7.5Median ^a^:0.8 for EAC and 0.9 for ESCC293 EAC220 ESCCIncident invasive cases: localized, regional, distant, unknownAlcoholBaseline interviews2 categories:non-drinkersand ever drinkers ^c^All-cause mortality ^d^:EAC:1.08 (0.81,1.44)ESCC:1.77 (0.93,3.35)None7Park et al. \[[@CR28]\], 2006, South KoreaA cohort of male participated in a national health examination programMean:2.05 (Max:6.8)272 ECNot collectedAlcoholA self-administered questionnaire3 categories(g of alcohol/week):0,0--124.1,≥124.2All-cause mortality1.44 (0.81,2.55)Age, BMI, fasting serum glucose level, cholesterol level, physical activity, food preference, blood pressure, and other comorbidities5Samadi et al. \[[@CR33]\], 2007, IranPatients initially diagnosed in Aras ClinicMax: 5122 ECDifferentiation:well, moderate/ poor, nondifferentiatedAlcoholQuestionnaire completed at the time of diagnosis2 categories: no and yesAll-cause mortality:7.51(0.82,69.10)Age, sex, residence, treatment, smoking, opium use, differentiation, education4Sundelof et al. \[[@CR14]\], 2008, SwedenNationwide case-control studyFrom 1994.12.1--1997.12.31 to 2004.12.31177 EAC159 ESCCTNM stage: I, II, III, IVAlcohol (including beer, wine and liquor)Computer-aided face-to-face interview with separate questions4 categories(g of pure alcohol/week): never, 1--15, 16--70, \> 70All-cause mortalityEAC:1.0 (0.5,1.7)ESCC:0.6 (0.3,1.4)Age, sex, educational level, symptomatic reflux, BMI, smoking, physical activity, tumor stage and for esophagectomy8Shitara et al. \[[@CR26]\], 2010, JapanPatients in Aichi Cancer Center HospitalMedian:5.6 (Min-Max: 2.1--7.9)363 ESCCUICC stage: I, II, III, IVAlcoholHERPACC questionnaire2 categories^e^ (g of ethanol/week): \<230 and ≥ 230All-cause mortality0.85(0.61,1.18)Age, sex, smoking, ECOG PS, tumor length, UICC stage, treatment7Lu et al. \[[@CR24]\], 2011, ChinaA new established patient cohortMedian: 3.5, (Min-Max: 0.03--4.66).120 ESCC patients underwent esophagectomyT stage: T1\~T4N stage: N0, N1M stage: M0, M1clinical stage: 1/2, 3/4AlcoholRisk factor questionnaire2 categories:Never drinkers and ever drinkersCancer-specific mortality:1.02(0.61--1.72)None6Jing et al. \[[@CR25]\], 2012, ChinaPatients in General Hospital of Chengdu Military AreaMedian:3.25(Min-Max: 0.25--5)167 ESCCT stage: T1\~T4N stage: N0, N1M stage: M0, M1AlcoholA 65-item self-administered structured questionnaire4 categories^f^ (g of ethanol/week): never, former, moderate, heavyCancer-specific mortality: 1.42(0.83,1.84)None5Thrift et al. \[[@CR29]\], 2012, AustraliaPopulation-based case-control studyMedian: 6.4(Min-Max: 4.8--8.9)301 ESCCAJCC stage: I, II, III, IVAlcohol (including light beer, regular beer, white wine, red wine, port/sherry and spirits/liqueur)A health and life style questionnaire4 categories(g of ethanol/week) \< 10, 10--60, 70--200, ≥210All-cause mortality ESCC:2.08 (1.18,3.69);Age, sex, AJCC stage, treatment intent, number of comorbidities and smoking7Thrift et al. \[[@CR31]\], 2012, AustraliaPopulation-based case-control studyMedian: 6.4(Min-Max: 4.8--8.9)362 EACAJCC stage: I, II, III, IVAlcohol (including light beer, regular beer, white wine, red wine, port/sherry and spirits/liqueur)A health and life style questionnaire4 categories(g of ethanol/week)\< 10, 10--60, 70--200, ≥210All-cause mortalityEAC: 1.02(0.64,1.64)Age, sex, AJCC stage, treatment intent, number of comorbidities and smoking7Wu et al. \[[@CR32]\], 2013, ChinaHospital-based case-control studyMax: 5718 ESCCAJCC stage: I + II, III + IVAlcoholA standardized questionnaire2 categories^g^:users and non-usersAll-cause mortality: 1.30(1.01,1.67);Age, sex, education levels and AJCC stages8Huang et al. \[[@CR27]\], 2014, ChinaProspectively created esophageal carcinoma databaseMedian:5.32151EC1851 ESCC,AJCC stage: 0 + I, II, IIIAlcohol (including wine, spirit and beer)Baseline interviews4 categories^h^ (g of alcohol/week):0, 0--90.09, 91--272.09, ≥273All-cause mortality ^d^:EC: 1.46(1.19,1.79)ESCC: 1.37(1.11,1.70)Age, sex, weight loss, stage, radicality of surgery, adjuvant treatment, smoking7Ma et al. \[[@CR15]\], 2016, ChinaEsophageal cancer database of the Department of Thoracic Surgery at Sun Yat-sen University Cancer CenterMedian: 6.5 (Min-Max:1--20)643 ESCC with negative lymphatic metastasis having undergone esophagectomyPost-operation staging of AJCC stage: IA, IB, IIAAlcoholMedical records2 categories^i^:non-drinkers and drinkersAll-cause mortality ^d^:1.58(1.21,2.07)Age, sex, smoking, family history, tumor location, surgery technique, post-operation staging, tumor grade7*HR* hazard ratio, *CI* confidence interval, *NOS* the Newcastle-Ottawa Quality assessment scale, *EC* esophageal cancer, *EAC* esophageal adenocarcinoma, *ESCC* esophageal squamous cell carcinoma, *FFQ* food frequency questionnaire, *NCI* National Cancer Institute, *NIH* National Institutes of Health, *BMI* body mass index, *Min* minimum, *Max* maximum, *TNM* tumor node metastasis, *HERPACC* Hospital-based Epidemiologic Research Program at Aichi Cancer Center, *ECOG PS* Eastern Cooperative Oncology Group performance status, *AJCC* American Joint Committee on Cancer, *UICC* Union for International Cancer Control^a^ Data of median survival time. Survival time in this article was defined as the time from the date of diagnosis to the date of death or last follow-up, same as the time of follow-up^b^ SB1, Sugars from soft drinks and fruit juices (g/day); SB2, Sugars from soft drinks, fruit juices, and sugar added to tea, coffee or cereal (g/day)^c^ Ever drinkers defined as those who had ≥1 alcoholic drink (12 oz. beer, 4 oz. glass of wine, 1 drink with hard liquor) per month for ≥6 months^d^ The outcome was overall survival (OS) defined as the time from diagnosis through death from any causes. Calculated HR was the same as that of all-cause mortality^e^ Calculated according to definition of drinking group in this article. It divided alcohol intake into 2 categories: non-heavy drinkers and heavy drinkers^f^ Former drinkers were those who quit drinking more than 1 year, heavy drinkers were those who drank alcoholic beverages ≥250 g of ethanol/week while moderate drinkers were defined as drinkers consuming \< 250 and \> 0 g of ethanol/week^g^ Users were defined as those who consumed alcoholic drinks ≥1 time /week for ≥6 months^h^ Calculated according to definition of drinking group in this article. It divided alcohol intake into 4 categories: non-drinkers, light drinkers, moderate drinkers and heavy drinkers^i^ Patients with a present or past history of alcohol consumption were referred to as drinkers

All of 15 included studies provided pre-diagnosis dietary exposure information. In terms of types of dietary exposure, 12 studies were on alcohol consumption \[[@CR14], [@CR15], [@CR23]--[@CR29], [@CR31]--[@CR33]\], two on dietary folate intake \[[@CR24], [@CR25]\], one on sugary beverage \[[@CR12]\], one on flavonoids and lignans \[[@CR13]\] and one on preserved vegetables \[[@CR30]\]. A total of 13 studies \[[@CR12]--[@CR15], [@CR23], [@CR26]--[@CR33]\] used all-cause mortality as outcome and the other two \[[@CR24], [@CR25]\] used esophageal cancer-specific mortality. Consumption of alcohol was measured using health behavior questionnaires, while intakes of dietary folate, flavonoids, preserved vegetables and sugary beverages were collected from validate modified food frequency questionnaire. Of the five studies not collecting information of stage and severity of esophageal cancer, one was focused on preserved vegetables \[[@CR30]\] and the other four on alcohol \[[@CR23]--[@CR25], [@CR28]\].

For study quality of 15 included studies, average NOS score was 6.65, ranging from 4 to 8; 12 studies were high quality (NOS score ≥ 7) and three studies were median quality.

Dietary folate intake {#Sec11}
---------------------

Only two studies \[[@CR24], [@CR25]\] reported effects of dietary folate intake on esophageal cancer-specific mortality in ESCC. These two studies provided adjusted risk estimates from multivariate analysis. Categorization of folate intake was different in these two studies. The highest vs. the lowest in one article \[[@CR24]\] was ≥95.5 μg/day vs. \< 30.0 μg/day, while in another article \[[@CR25]\] was \> 300μg/day vs. \< 230μg/day. When pooled these two studies (Fig. [2](#Fig2){ref-type="fig"}), the overall HR was 0.41 (95% CI: 0.25--0.69) with low statistical heterogeneity (*P*~for\ heterogeneity~ = 0.79, *I*^2^ = 0%). The funnel plot did not reveal asymmetry (Fig. [3](#Fig3){ref-type="fig"}) and the corresponding Begg's test did not show publication bias (*P* = 1.00). Power calculation for random effect model was 96.5%. Fig. 2Forest plot of association between dietary folate intake (highest vs. lowest) and esophageal cancer-specific mortality among patients with esophageal squamous cell carcinomaFig. 3The funnel plot with Pseudo 95% confidence limits on dietary folate intake and esophageal cancer-specific mortality among patients with esophageal squamous cell carcinoma

Other dietary components {#Sec12}
------------------------

Only one study on sugary beverages \[[@CR12]\], one on phytochemicals \[[@CR13]\] and one on preserved vegetables \[[@CR30]\] were found. Miles et al. \[[@CR12]\] studied effects of sugary beverages intake on prognosis of EC and EAC. They found that soft drinks and fruit juices intake would worsen prognosis of EC patients; however, when the study population was restricted to patients with EAC, no significant association between sugary beverages and all-cause mortality was found. Petrick et al. \[[@CR13]\] studied effects of consumption of total dietary flavonoids, dietary flavonoid subclasses (anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols and isoflavones) and lignans on all-cause mortality in ESCC and EAC, respectively; however, only lignans was found to reduce all-cause mortality of ESCC by 42% (HR = 0.58, 95% CI: 0.37--0.92). As indicated in a study done by Shi et al. \[[@CR30]\], in ESCC patients, when comparing with patients consuming preserved vegetables \< 1 time/week, those who consumed preserved vegetables ≥1time/week had a 1.58-fold (95% CI: 1.01--2.47) risk of all-cause mortality.

Alcohol consumption {#Sec13}
-------------------

A total of ten studies \[[@CR14], [@CR15], [@CR23], [@CR26]--[@CR29], [@CR31]--[@CR33]\] investigated effects of alcohol consumption on all-cause mortality and the other two studies \[[@CR24], [@CR25]\] on esophageal cancer-specific mortality (Table [1](#Tab1){ref-type="table"}). The reference group (the lowest group) in nine studies \[[@CR14], [@CR15], [@CR23]--[@CR25], [@CR27], [@CR28], [@CR32], [@CR33]\] was non-drinkers, in two studies \[[@CR29], [@CR31]\] was those consuming \< 10 g ethanol per week, and in one study \[[@CR26]\] was non-heavy drinkers. The highest group was defined as ever drinkers \[[@CR23], [@CR24]\], or current drinkers \[[@CR15], [@CR32], [@CR33]\], or group with the highest level of alcohol consumption \[[@CR14], [@CR25]--[@CR29], [@CR31]\]. Only five studies \[[@CR23]--[@CR26], [@CR29]\] was available to estimate the risk by using univariate analysis (Table [2](#Tab2){ref-type="table"}). Table 2Hazard ratios (HRs) with 95% confidence intervals (CIs) for alcohol consumption and mortality of esophageal cancer by histological typeStudy ID ^a^Crude\
HR (95% CI) ^b^Adjusted\
HR (95% CI) ^b^Heterogeneity for\
pooled crude HRHeterogeneity for\
pooled adjusted HR*I*^2^ (%)*PI*^2^ (%)*P*EC//4.20.352 Huang et al. \[[@CR27]\]1.46 (1.19,1.79) Samadi et al. \[[@CR33]\]7.51 (0.82, 69.10) Park et al. \[[@CR28]\]1.44 (0.81, 2.55)pooled estimates1.48 (1.19, 1.84)ESCC77.80.00166.90.010 Huang et al. \[[@CR27]\]1.37 (1.11, 1.70) Ma et al. \[[@CR15]\]1.58 (1.21, 2.07) Shitara et al. \[[@CR26]\]0.87 (0.65, 1.17)0.85 (0.61, 1.18) Sundelof et al. \[[@CR14]\]0.60 (0.30, 1.40) Thrift et al. \[[@CR29]\]2.51 (1.63, 3.85)2.08 (1.18, 3.69) Trivers et al. \[[@CR23]\]1.77 (0.93, 3.35) Wu et al. \[[@CR32]\]1.30 (1.01, 1.67) Jing et al. \[[@CR25]\]1.42 (0.83, 1.84) Lu et al. \[[@CR24]\]1.02 (0.61, 1.72)pooled estimates1.27 (1.06, 1.53)1.26(1.01, 1.60)EAC//0.00.960 Sundelof et al. \[[@CR14]\]1.00 (0.50, 1.70) Thrift et al. \[[@CR31]\]1.02 (0.64, 1.64) Trivers et al. \[[@CR23]\]1.08 (0.81, 1.44)pooled estimates1.01 (0.70, 1.47)^a^*EC* esophageal cancer, *ESCC* esophageal squamous cell carcinoma, *EAC* esophageal adenocarcinoma, *HR* hazard ratio, *CI* confidence interval^b^ The effect was estimated by comparing the highest with the lowest consumption of alcohol

The pooled results of the association between alcohol consumption and risk of death among different subtypes of esophageal cancer are shown in Fig. [4](#Fig4){ref-type="fig"}. When comparing the highest with lowest consumption of alcohol, the pooled HR was 1.48 (95% CI: 1.19--1.84) with low statistical heterogeneity (*P*~for\ heterogeneity~ = 0.35, *I*^2^ = 4.2%) in EC and 1.29 (95% CI: 1.07--1.55) with moderate statistical heterogeneity (*P*~for\ heterogeneity~ = 0.03, *I*^2^ = 53.0%) in ESCC, whereas no association was found in EAC (HR = 1.05, 95% CI: 0.84--1.32). The funnel plots did not show significant asymmetry for any types of esophageal cancer (Fig. [5](#Fig5){ref-type="fig"}), and the corresponding Begg's tests did not show publication bias (all *P* \> 0.30). Power calculation for these three random effect models was all equal to 100.0%. Fig. 4Forest plot of association between alcohol consumption (highest vs. lowest) and risk of mortality by cancer type. Abbreviation: EC, esophageal cancer; EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinomaFig. 5The funnel plot with Pseudo 95% confidence limits on alcohol consumption and risk of mortality by cancer type

The sensitivity analysis was only performed on alcohol consumption. The analysis was repeated consecutively by removing one study from the pooled results each time, and significant change was observed only after the exclusion of Huang's study \[[@CR27]\] in EC and ESCC, respectively (Supplementary Fig. [S1](#MOESM1){ref-type="media"}); the analysis was also conducted by excluding 3 studies \[[@CR23]--[@CR25]\] not reporting adjusted effect size, and the pooled results were 1.26 (95% CI: 1.01--1.60) for ESCC and 1.01(95% CI: 0.70--1.47) for EAC (Table [2](#Tab2){ref-type="table"}). When the unadjusted effect was considered, the pooled HR was 1.27 (95% CI: 1.06--1.53) for ESCC. Only one study \[[@CR23]\] on EAC provided crude effect; hence, the pooled analysis was not conducted (Table [2](#Tab2){ref-type="table"}). When the studies which did not include information of stage and severity of esophageal cancer were excluded, the pooled HR was 1.26 (95% CI: 1.01--1.60) for ESCC and 1.01(95% CI: 0.70--1.47) for EAC.

Discussion {#Sec14}
==========

As far as we know, there lacks of systematic review with quantitative analysis to evaluate ordinary dietary behavior and prognosis of esophageal cancer. The results from meta-analysis displayed that pre-diagnostic dietary folate intake was significantly related to a decreased risk of esophageal cancer-specific mortality in ESCC and pre-diagnostic alcohol consumption was associated with an increased risk of all-cause mortality in EC and in ESCC.

Alcohol is one of the major determinant factors for developing esophageal cancer \[[@CR34]\], but effects of it on esophageal cancer prognosis remain controversial \[[@CR16]\]. The pooled results in our study showed that pre-diagnostic alcohol consumption could increase risk of mortality among EC and ESCC patients by 48 and 29% respectively; however, this effect was not found in EAC patients. Without adjustments, confounding factors could lead to misinterpretation of the association between independent variables and dependent variables \[[@CR35]\]. Hence, we pooled crude HRs obtained from univariate analysis and adjusted HRs obtained from multivariate analysis, respectively; the association remained the same, further suggesting the strong effects of alcohol intake on ESCC mortality and indicating that our results was stable and robust. Similar results were obtained when the studies not including information of stage and severity of esophageal cancer were excluded. The findings from our study are consistent with the results from a previous meta-analysis by Fahey et al. \[[@CR16]\], though the contrast groups were different between two studies. To examine the robustness of our results, we repeated the analysis by excluding the study one by one from the pooled results, and no significant change was observed for ESCC and EAC with the exception of excluding the study by Huang et al. \[[@CR27]\], indicating the results our study obtained were stable. Omitting the study by Huang et al. \[[@CR27]\] altered the positive association between alcohol consumption and risk of death in EC and ESCC to no association. This may be due to that the sample size of this study was the largest, therefore the weight of the study was relatively large when calculating the pooled results, indicating that more studies with large scale samples are needed.

Our results of meta-analysis also indicated that intake of dietary folate was associated with 59% reduced risk of esophageal cancer-specific mortality among ESCC patients. This finding is consistent with findings on other cancers \[[@CR36], [@CR37]\]. Folate metabolites have become diagnostic and therapeutic targets for several types of cancers in recent years \[[@CR38], [@CR39]\]. The possible mechanism maybe due to that folate deficiency indirectly affects DNA and RNA methylation, thereby alters the expression of tumor suppressor genes and proto-oncogenes \[[@CR40], [@CR41]\]. However, only two studies focused on effects of dietary folate intake on EC mortality, and all were carried out in China with small sample size. Thus, replication of our results in other large studies in different countries is warranted.

The evidence for other dietary components is limited. Lignans was found to reduce risk of all-cause mortality of ESCC by 42% \[[@CR12]\], while positive association between the other two factors, sugary beverages and preserved vegetables, and esophageal cancer survival was revealed \[[@CR13], [@CR30]\]. Sugar in food can lead to awful disease progression through increased inflammation. The inflammation can be caused by oxidative stress, which ultimately accelerates DNA damage and elevates levels of interleukin-cytokines and other pro-inflammatory molecules \[[@CR42]\]. N-nitroso compounds widely existing in processed foods (eg. preserved vegetables) may play an important role in tumor progression. N-nitroso compounds give rise to excessive expression of cyclinE 1, cyclinD 1, transform growth factor α and epidermal growth factor receptor in esophageal tissues, thus enhance cancer progression \[[@CR43]\]. Anti-cancer effects of phytochemicals like lignans are mainly through estrogen/anti-estrogen activity, anti-proliferation or apoptosis, prevention of oxidation, induction of cell cycle arrest, regulation of changes in host immune system, anti-inflammatory activity and cell signal transduction \[[@CR44]\].

This study has some strengths. First, the literature retrieval was from multiple databases and the selection was determined by independent reviewers, which was helpful to avoid literature omission. Second, we included studies according to the strict inclusion and exclusion criteria, which may augment the validity of our findings. Third, sensitivity analyses yielded similar results, indicating the stability of our findings.

There were also some limitations in this study. There were only 15 studies included; most of them focused on alcohol consumption and only five focused on other dietary components; pooling results from limited evidence may influence the stability of our results, though the power of random effect models in our study is fairly strong and sensitivity analyses yield similar results. Consuming large amounts of fruits and vegetables after diagnosis could reduce the mortality of cancer and diets before diagnosis may reflect the changes in taste or appetite attributable to cancer \[[@CR45]\]. Besides, cancer patients may follow the doctor's advice to change their diets in order to obtain better prognosis. However, dietary behaviors in this systematic review and meta-analysis were all pre-diagnostic, the roles of post-diagnostic dietary intake in prognosis of esophageal cancer are unclear.

Conclusion {#Sec15}
==========

In summary, this review with limited evidence suggested that folate intake was associated with a reduced risk of esophageal cancer-specific mortality for ESCC, whereas alcohol consumption was associated with increased risk of mortality for ESCC. More studies are needed to investigate effect of dietary factors, especially post-diagnosis dietary consumption, on esophageal cancer prognosis.

Supplementary information
=========================
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**Additional file 1: Figure S1**. Summary of sensitivity analyses of alcohol consumption and mortality among (a) EC (b) ESCC (c) EAC. Abbreviation: HR, hazard ratio; CI, confidence interval; EC, esophageal cancer; EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma.

CI

:   Confidence interval

EC

:   Esophageal cancer

ESCC

:   Esophageal squamous cell carcinoma

EAC

:   Esophageal adenocarcinoma

HR

:   Hazard ratio HR

NOS

:   Newcastle-Ottawa Scale
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